



JAN 12 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, USPTO

PTO/SB/08A (08-03)

Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/572,696
Filing Date	October 5, 2006
	International Filing Date: September 18, 2003
First Named Inventor	Edith Gardiner
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	42-000400US
Date Submitted	January 8, 2007

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,968,819		Gerald et al.	10/19/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	2	WO	00/00606 A1		Garvan Inst of Med Rsch.	01/06/2000		
	3	WO	01/53477 A1		Baylor Coll of Med.	07/26/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
4	BALDOCK ET AL. (2002) Hypothalamic Y2 receptors regulate bone formation . J. Clin Invest. 109(7) 915-921.		
5	BLOCK ET AL. (2002) Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J. Med Chem.45:3509-3523.		
6	CABRELE ET AL. (2000) Molecular characterisation of the ligand-receptor interaction of the neuropeptide Y family. J. Peptide Sci 6:97-122.		
7	CHAMORRO ET AL. (2002) Appetite suppression based on selective inhibition of NPY receptors. Int. J. Obes. 26:281-298		
8	DUHAULT ET AL. (2000) Food intake in rodents: Y5 or Y1 NPY receptors or both? Can J. Physiol Pharm. 78:173-185.		
9	HANSEL ET AL. (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (6831) 940-944.		
10	HERZOG (2002) Hypothalamic Y2 receptors: central coordination of energy homeostasis and bone mass regulation. Drug News Perspect 15(8): 506-510.		
11	IYENGAR ET AL. (1999) Characterzation of neuropeptide Y induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding? J. Pharm Exp Ther. Whole document.		
12	KUSHI ET AL. (1998) Obesity and mild hyperinsulinaemia found in neuropeptide Y-Y1 receptor deficientmice. Proc Nat Acad Sci USA 95:15659-64		
13	PARKER ET AL. (2002) Neuropeptide Y receptors as targets for anti-obesity drug		

Examiner Signature	/Ruixiang Li/	Date Considered	03/23/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A-B/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>	<p>Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 45%;">Application Number</td> <td style="width: 55%;">10/572,696</td> </tr> <tr> <td>Filing Date</td> <td>October 5, 2006</td> </tr> <tr> <td></td> <td>International Filing Date: September 18, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Edith Gardiner</td> </tr> <tr> <td>Group Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>42-000400US</td> </tr> <tr> <td>Date Submitted</td> <td>January 8, 2007</td> </tr> </table>	Application Number	10/572,696	Filing Date	October 5, 2006		International Filing Date: September 18, 2003	First Named Inventor	Edith Gardiner	Group Art Unit	1646	Examiner Name	Unassigned	Attorney Docket Number	42-000400US	Date Submitted	January 8, 2007
Application Number	10/572,696																
Filing Date	October 5, 2006																
	International Filing Date: September 18, 2003																
First Named Inventor	Edith Gardiner																
Group Art Unit	1646																
Examiner Name	Unassigned																
Attorney Docket Number	42-000400US																
Date Submitted	January 8, 2007																

	development: perspective and current status. Eur J. Pharm 440:173-187	
14	SAINSBURY ET AL. (2002) Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Nat Acad Sci USA 99(3):8938-8943.	
15	SAINSBURY ET AL. (2003) Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 15:5225-5233.	
16	TANG-CHRISTENSEN ET AL. (1998) Central administration of Y5 antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J. Endo 159:307-312.	
17	Copy of International Search Report for PCT/AU03/01227	
18	Copy of Written Opinion for PCT/AU03/01227	
19	Copy of International Preliminary Examination Report for PCT/AU03/01227	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./

Examiner Signature	/Ruixiang Li/	Date Considered	03/23/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.